الإحصائيات الأساسية
| CIK | 1506184 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Immutep Limited
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| September 3, 2025 |
APPENDIX 4E PRELIMINARY FINAL REPORT EX-99.1 Exhibit 99.1 Immutep Limited Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2025 Previous corresponding period: Year ended 30 June 2024 2. Results for announcement to the market FY2024 FY2025 Revenue from ordinary activities No change — to — Other income Up 7,838,625 |
|
| September 3, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as August 29, 2025 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney |
|
| August 7, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as August 05, 2025 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney |
|
| August 7, 2025 |
EX-99.1 Exhibit 99.1 Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1 SYDNEY, AUSTRALIA – August 5th, 2025 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and construc |
|
| July 31, 2025 |
Immutep Quarterly Activities Report & Appendix 4C Q4 FY25 EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q4 FY25 • The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and countries • Trial-in-Progress poster for TACTI-004 presented at the 2025 American Society for Clinical |
|
| July 31, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as July 30, 2025 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NS |
|
| June 24, 2025 |
Exhibit 99.1 Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases • Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg • The substantial reduction in T cell activity highlights the potential effi |
|
| June 24, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as June 23, 2025 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NS |
|
| May 28, 2025 |
EX-99.1 Exhibit 99.1 Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma • Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcoma • Detailed results are planned for presentation at a future medical meeting SYDNEY, |
|
| May 28, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as May 26, 2025 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as May 15, 2025 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 200 |
|
| May 16, 2025 |
Exhibit 99.1 Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer • Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC) • Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including 43% with PD-L1 below 1 (TPS <1%), who represent an |
|
| May 6, 2025 |
Exhibit 99.1 Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1 • Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1 • Mature overall survival data builds on encouraging high response rates with multiple complete respon |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as May 5, 2025 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 2000 |
|
| April 30, 2025 |
Immutep Quarterly Activities Report & Appendix 4C Q3 FY25 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q3 FY25 • First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestone • Pivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025 • Patient enrolment completed for the EFTISARC-NEO Phase II trial evaluating efti with radiotherapy and KEYTRUDA® in |
|
| April 30, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as April 29, 2025 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney N |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as March 25, 2025 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 2 |
|
| March 26, 2025 |
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer Exhibit 99.1 First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer • First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep • Global Phase III with efti will enrol approximately 756 patients at more than 150 clinical sites • Trial results will inform potential marketing approval applicat |
|
| February 27, 2025 |
Exhibit 99.1 IMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2024 (previous corresponding period: half-year ended 31 December 2023) To be read in conjunction with the 30 June 2024 Annual Report. In compliance with Listing Rule 4.2A. ABN 90 009 237 889 ASX/Media Release (ASX: IMM) 26 February 2025 Appendix 4D Half-Year Financial Report R |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as February 26, 2025 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NS |
|
| February 3, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as January 31, 2025 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney |
|
| February 3, 2025 |
Immutep Quarterly Activities Report & Appendix 4C Q2 FY25 EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q2 FY25 • Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval • Mature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival (OS) and 81.0% 24-m |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as December 17, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NS |
|
| December 17, 2024 |
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 Exhibit 99.1 Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 • Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to date • Additional safety data and assessment of PK/PD relationships to follow in first half of CY2025 • IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restor |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as December 12, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NS |
|
| December 12, 2024 |
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 Exhibit 99.1 Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 • Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1 • Positively, median overall survival (OS) has not yet been reached and the 12-month |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as December 10, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NS |
|
| December 10, 2024 |
Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer Exhibit 99.1 Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer SYDNEY, AUSTRALIA – December 10, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the initiation of the pivotal TACTI-004 Phase II |
|
| November 15, 2024 |
Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting EX-99.1 Exhibit 99.1 Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting • Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma • Over three-fold increase in tumour hyalinization, the primary endpoint of the study and an important predictor of overall surv |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as November 14, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NS |
|
| November 15, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as November 14, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydne |
|
| November 15, 2024 |
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer EX-99.1 Exhibit 99.1 Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer • Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: • Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall S |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as October 29, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW |
|
| October 30, 2024 |
Immutep Quarterly Activities Report & Appendix 4C Q1 FY25 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q1 FY25 • Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the trial design • Efti in combination with MSD’s KEYTRUDA® reports positive efficacy and favourable safety in first-line head and neck |
|
| October 22, 2024 |
Immutep Limited Policy on Recovery of Erroneously Awarded Incentive Compensation EX-97.1 Exhibit 97.1 Immutep Limited Policy on Recovery of Erroneously Awarded Incentive Compensation Introduction Immutep Limited (the “Company”) is listed on Nasdaq and, as such, is subject to the requirements of the US Securities Exchange Act of 1934 and rules promulgated by the US Securities and Exchange Commission. In 2023, the SEC issued new Rule 10D-1, which requires US stock exchanges to a |
|
| October 22, 2024 |
Exhibit 4.15 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Clinical Trial Collaboration and Supply Agreement by and between MSD International Business GmbH and Collaborator (as defined below |
|
| October 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|
| October 22, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-15.1 Exhibit 15.1 Immutep Limited Level 32, Australia Square 264 George Street Sydney NSW 2000 Australia CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (No. 333-271484) of Immutep Limited of our report dated October 22, 2024 relating to the financial statements and the effectiveness of intern |
|
| October 22, 2024 |
EX-12.1 Exhibit 12.1 Certification of the Chief Executive Officer and Chief Financial Officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, Marc Voigt, certify that: 1. I have reviewed this annual report on Form 20-F of Immutep Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary |
|
| October 22, 2024 |
EX-13.1 Exhibit 13.1 Certification of the Chief Executive Officer and Chief Financial Officer as required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Marc Voigt, Chief Ex |
|
| October 3, 2024 |
Exhibit 99.1 Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer SYDNEY, AUSTRALIA – October 03, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces patient enrolment has been completed in th |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as October 3, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW |
|
| September 24, 2024 |
Immutep Receives A$3.6 million R&D Tax Incentive from French Government EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Receives A$3.6 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA – 24 September 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €2,194,918 (~ A$3,627 |
|
| September 24, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as September 24, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydn |
|
| September 17, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as September 16, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydn |
|
| September 17, 2024 |
EX-99.1 Exhibit 99.1 Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer • Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 • In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in CPS ≥20 with 31.0% ORR (34.5% ORR inclu |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as September 9, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NS |
|
| September 10, 2024 |
Exhibit 99.1 INDEX ANNOUNCEMENT S&P Dow Jones Indices Announces September 2024 Quarterly Rebalance of the S&P/ASX Indices SYDNEY, SEPTEMBER 6, 2024: S&P Dow Jones Indices announced today the changes in the S&P/ASX Indices, effective prior to the open of trading on Monday, September 23, 2024, as a result of the September quarterly review. S&P/ASX 20 Index – No change. S&P/ASX 50 Index – No change. |
|
| September 3, 2024 |
APPENDIX 4E PRELIMINARY FINAL REPORT Exhibit 99.1 Immutep Limited Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2024 Previous corresponding period: Year ended 30 June 2023 2. Results for announcement to the market FY2023 FY2024 Revenue from ordinary activities No change — to — Other income Up 5,200,128 to 7,83 |
|
| September 3, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as August 30, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as August 20, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW |
|
| August 21, 2024 |
Exhibit 99.1 ASX/Media Release Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024 • Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck squamous cell carcinoma patients with any PD-L1 expression (CPS >1) SYDNEY, AUSTRALIA – 20 August 2024 – Immutep Limited (ASX: IMM; NASDAQ: I |
|
| August 15, 2024 |
Exhibit 99.1 ASX/Media Release Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody • IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases • Safety data from this first-in-human study anticipated by year-end and pharmacokine |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as August 14, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as July 31, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 20 |
|
| August 1, 2024 |
Immutep Quarterly Activities Report & Appendix 4C Q4 FY24 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q4 FY24 • Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line non-small cell lung cancer in a pivotal Phase III trial • Continuing positive clinical dat |
|
| July 23, 2024 |
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer Exhibit 99.1 ASX/Media Release Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer • Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lun |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as July 22, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 20 |
|
| July 17, 2024 |
Exhibit 99.1 ASX/Media Release Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases • Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA – 17 July 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immu |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as July 17, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 20 |
|
| July 15, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as July 12, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NS |
|
| July 15, 2024 |
Exhibit 99.1 Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression • Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 • High complete res |
|
| July 3, 2024 |
Exhibit 99.1 Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July) SYDNEY, AUSTRALIA – July 3rd, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as July 3, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 200 |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as June 27, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 20 |
|
| June 28, 2024 |
Exhibit 99.1 Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer • Efti in combination with KEYTRUDA® (pembrolizumab) in first line head and neck squamous cell carcinoma (1L HNSCC) led to overall response rates that exceed KEYTRUDA monotherapy across all levels of PD-L1 expression • In the randomised, controlled Cohort A, the combination shows |
|
| June 25, 2024 |
Exhibit 99.1 ASX/Media Release Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer SYDNEY, AUSTRALIA – 25 June 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces a License Agree |
|
| June 25, 2024 |
NOT FOR DISTRIBUTION OR RELEASE TO U.S. WIRE SERVICES IN THE UNITED STATES Exhibit 99.1 NOT FOR DISTRIBUTION OR RELEASE TO U.S. WIRE SERVICES IN THE UNITED STATES 24 June 2024 Immutep completes underwritten retail entitlement offer Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or the Company) is pleased to announce the completion of the retail component of its fully underwritten Entitlement Offer (details of which were announced to the market on 3 June 2024) (Retai |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as June 24, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 20 |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as June 25, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 20 |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as June 05, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 20 |
|
| June 6, 2024 |
Exhibit 99.1 5 June 2024 Immutep successfully completes institutional placement and institutional component of entitlement offer Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 for 16 pro rata accele |
|
| June 4, 2024 |
EX-99.1 Exhibit 99.1 Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial • Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) • TACTI-004 Phase III trial will enrol approximately 750 pati |
|
| June 4, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as June 03, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NS |
|
| May 16, 2024 |
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 EX-99.1 Exhibit 99.1 Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 • Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxel • Ongoing complete response has been maintained since the patient started treatment with efti monotherapy • Efti + pac |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as May 15, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 200 |
|
| May 3, 2024 |
Exhibit 99.1 ASX/Media Release Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma • Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial • Four of six patients treated have very |
|
| May 3, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as May 02, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW |
|
| April 30, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as April 29, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney N |
|
| April 30, 2024 |
Immutep Quarterly Activities Report & Appendix 4C Q3 FY24 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q3 FY24 • First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patient reporting a complete response (complete disappearance of all lesions), and a 100% disease control rate • Subsequent to quart |
|
| April 25, 2024 |
Exhibit 99.1 Immutep Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA® (pembrolizumab) in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression • Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TA |
|
| April 25, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as April 24, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney N |
|
| April 19, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as April 18, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney N |
|
| April 19, 2024 |
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 Exhibit 99.1 ASX/Media Release Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 • Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune diseases • CHDR will utilize its unique challenge mo |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as March 5, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW 20 |
|
| March 6, 2024 |
Immutep Announces First Clinical Data from 90mg Dosing of Efti Exhibit 99.1 Immutep Announces First Clinical Data from 90mg Dosing of Efti • Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well tolerated • Encouraging initial efficacy in six metastatic breast cancer patients, who exhausted all endocrine therapy including CDK4/6 inhibitors, demonstrated by a 50% overall response rate, including one |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as February 28, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NS |
|
| February 29, 2024 |
Exhibit 99.1 IMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2023 (previous corresponding period: half-year ended 31 December 2022) To be read in conjunction with the 30 June 2023 Annual Report. In compliance with Listing Rule 4.2A. ABN 90 009 237 889 ASX/Media Release (ASX: IMM) 28 February 2024 Appendix 4D Half-Year Financial Report R |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as January 30, 2024 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 32, Australia Square 264 George Street, Sydney NSW |
|
| January 30, 2024 |
Immutep Quarterly Activities Report & Appendix 4C Q2 FY24 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q2 FY24 • Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing PD-L1 (TPS ≥1%) • Promising efficacy and tolerability data reported from INSIGHT-003 Phase I trial, including a strong Overa |
|
| December 21, 2023 |
Exhibit 99.1 Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer SYDNEY, AUSTRALIA – December 21, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces constructive feedback |
|
| December 21, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as December 21, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydne |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as December 7, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| December 8, 2023 |
Immutep Receives A$2.6 million R&D Tax Incentive from French Government Exhibit 99.1 ASX/Media Release Immutep Receives A$2.6 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA – 7 December 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €1,595,475 (~ A$2,628,354 ) res |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as November 9, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| November 9, 2023 |
Exhibit 99.1 ASX/Media Release Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma • A total of 171 head and neck squamous cell carcinoma (HNSCC) patients enrolled in randomised, multicentre Phase IIb trial evaluating efti in combination with pembrolizumab • Efti has FDA Fast Track designation f |
|
| November 6, 2023 |
Exhibit 99.1 ASX/Media Release Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer • No safety or tolerability issues in open-label, safety lead-in phase evaluating the higher 90mg dose of efti in combination with weekly paclitaxel in the first 6 patients • Good safety profile allows for lead-in p |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as November 6, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 3, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| November 3, 2023 |
Exhibit 99.1 ASX/Media Release Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer • Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved clinical outcomes • Early increase in absolute lymphocyte count is co |
|
| November 1, 2023 |
Immutep Quarterly Activities Report & Appendix 4C Q1 FY24 EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q1 FY24 • Excellent survival benefit in 1st line non-small cell lung cancer (1L NSCLC) in TACTI-002 trial: median Overall Survival of 35.5 months (TPS ≥1% patients) providing additional 12-18 months survival compared to historical data, reported post period • Late-stage & registrational trial progress: • 1st l |
|
| November 1, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 31, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney N |
|
| October 25, 2023 |
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023 Exhibit 99.1 ASX/Media Release Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023 • Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line therapy in metastatic non-squamous non-small cell lung cancer continues • Strong 71.4% Overall Response Rate, 90.5% Disease Control Rate, 10.1-month median Progressi |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 25, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| October 25, 2023 |
Immutep receives ~A$1.13 million R&D Tax Incentive Exhibit 99.1 ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 25 October 2023 Immutep receives ~A$1.13 million R&D Tax Incentive SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of exp |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 24, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| October 24, 2023 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-15.1 Exhibit 15.1 Immutep Limited 264 George Street Sydney NSW 2000 Australia CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (No. 333-271484) of Immutep Limited of our report dated October 24, 2023 relating to the financial statements and the effectiveness of internal control over financial r |
|
| October 24, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|
| October 24, 2023 |
EX-13.1 Exhibit 13.1 Certification of the Chief Executive Officer and Chief Financial Officer as required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Marc Voigt, Chief Ex |
|
| October 24, 2023 |
EX-12.1 Exhibit 12.1 Certification of the Chief Executive Officer and Chief Financial Officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, Marc Voigt, certify that: 1. I have reviewed this annual report on Form 20-F of Immutep Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 23, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| October 24, 2023 |
Exhibit 11.1 Securities Trading Policy Purpose This Securities trading policy (Policy) sets out the policy of the Company regarding the trading in Company securities. In this Policy: • Securities include shares as well as options, warrants, debentures and any other security on issue from time to time. Scope This policy applies to all Executive and Non-executive directors, officers and employees of |
|
| October 24, 2023 |
Exhibit 99.1 ASX/Media Release Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer • Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not b |
|
| October 17, 2023 |
Immutep Announces Publication of Abstracts at ESMO Congress 2023 EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Announces Publication of Abstracts at ESMO Congress 2023 • New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CEST • Immutep to host webcast to discuss ESMO 2023 clinical data on Monday, October 23rd, at 8AM AEDT (Sunday, October 22nd, at 5PM E |
|
| October 17, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 16, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney N |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated September 21, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| September 21, 2023 |
Exhibit 99.1 ASX/Media Release Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved SYDNEY, AUSTRALIA – September 21, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 im |
|
| August 2, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated August 1, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| August 2, 2023 |
Immutep Receives Positive Scientific Advice from European Medicines Agency EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Receives Positive Scientific Advice from European Medicines Agency SYDNEY, AUSTRALIA – 1 August 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive scientific advice from th |
|
| August 1, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated July 31, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| August 1, 2023 |
Immutep Quarterly Activities Report & Appendix 4C Q4 FY23 EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q4 FY23 Late-stage & registrational trial progress: • TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational trial in 1st line non-small cell lung cancer (1L NSCLC) • TACTI-003 Phase IIb – Randomised study in 1st line head & neck squamous cell carcinoma (1L HNSCC) has reached ~ |
|
| July 28, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated July 28, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| July 28, 2023 |
Exhibit 99.1 ASX announcement First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma SYDNEY, AUSTRALIA – 28 July 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enr |
|
| June 28, 2023 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor SYDNEY, AUSTRALIA – 27 June 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,684,654) |
|
| June 28, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated 6/27/2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2000 |
|
| June 21, 2023 |
6-K 1 d505238d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated June 20, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 Georg |
|
| June 21, 2023 |
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3 EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3 SYDNEY, AUSTRALIA – 20 June 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,680,104) by the Uni |
|
| June 6, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated June 5, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| June 6, 2023 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting • Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in TACTI-002 Phase II • Promising efficacy in patients with a PD-L1 |
|
| June 5, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated June 02, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| June 5, 2023 |
EX-99.1 Exhibit 99.1 2 June 2023 Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the Company), is pleased to announce the successful completion of an institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 fo |
|
| May 31, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated May 30, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| May 31, 2023 |
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study • Appointment of Charles River Laboratories (“Charles River”) to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761 • Forms a key step prior to first-in-human trials for this first-in-class LAG-3 agonist antibody designed to treat the underlying c |
|
| May 26, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated May 26, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| May 26, 2023 |
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting • New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma • Deep, durable responses seen across all PD-L1 subgroups with a 13.5% Complete Response rate and median Duration of Re |
|
| May 25, 2023 |
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial • Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of efficacy • Triple combination therapy has achieved a 67% response rate and 91% dis |
|
| May 25, 2023 |
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer SYDNEY, AUSTRALIA – 25 May 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enrolled an |
|
| May 25, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated May 24, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| May 25, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated May 25, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| May 17, 2023 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer • Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI-002 trial • Initial median Overa |
|
| May 17, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated May 17, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| May 16, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated May 16, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| May 16, 2023 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer SYDNEY, AUSTRALIA – 16 May 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announc |
|
| May 3, 2023 |
Immutep Limited Level 33, Australia Square 264 George Street Sydney, 2000 New South Wales CORRESP Immutep Limited Level 33, Australia Square 264 George Street Sydney, 2000 New South Wales Australia May 3, 2023 via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 2, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated May 1, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW 20 |
|
| May 2, 2023 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO® • Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO® in metastatic urothelial cancer • Trial builds on strategy to cost-effici |
|
| April 28, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) Immutep Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Ordinary shares (2) (3) (4) Other Warrants (2) (3) (4) Unallocated (Universal) Shelf 457(o) (2) (3) $100,000,000(4) $0. |
|
| April 28, 2023 |
Immutep Quarterly Activities Report & Appendix 4C Q3 FY23 EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q3 FY23 • Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast cancer • Positive final data reported from patients with 2nd line non-small cell lung cancer refractory to anti-PD-(L)1 therapie |
|
| April 28, 2023 |
Constitution of Immutep Limited adopted on November 26, 2021 EX-3.1 Exhibit 3.1 Constitution Immutep Limited ACN 009 237 889 Table of Contents 1. Definition and Interpretation 4 2. Exercise of powers 6 3. Share capital 7 4. Brokerage and commission 9 5. Ownership of Securities 9 6. Variation of class rights 9 7. Certificates 10 8. Calls on shares 11 9. Forfeiture of Securities 12 10. Lien 13 11. Sale of Unmarketable Parcels of Shares 14 12. Transfer of Secu |
|
| April 28, 2023 |
As filed with the Securities and Exchange Commission on April 28, 2023 F-3 Table of Contents As filed with the Securities and Exchange Commission on April 28, 2023 Registration No. |
|
| April 28, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated April 27, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| April 18, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated April 17, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydne |
|
| April 18, 2023 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting • Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosis • First time efti will be studied in neoadjuvant, non-metastatic cancer setting • Novel triple combination of efti with radiotherapy and anti-PD |
|
| April 11, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated April 11, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| April 11, 2023 |
Immutep Announces Changes to the Board EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Announces Changes to the Board SYDNEY, AUSTRALIA – 11 April 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces that Lis Boyce has been appointed as Non-Executive Director. She replaces Lucy Turnbu |
|
| April 3, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated March 31, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| April 3, 2023 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023 • Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care chemotherapy • 83% of patients stu |
|
| March 31, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated March 30, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| March 31, 2023 |
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer • Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patients • Expansion based on safety and strong initial efficacy results • Data updates expected throughout CY2023 and cost-efficient approa |
|
| March 14, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated March 14, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| March 14, 2023 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer • Integrated Phase II/III trial design incorporates feedback from the FDA and EMA and will help inform a BLA and MAA • HR+/HER2-neg/low metastatic breast cancer (MBC) patient population has been expanded to include triple-negative breast cancer |
|
| February 27, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated February 24, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney |
|
| February 27, 2023 |
EX-99.1 Exhibit 99.1 IMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2022 (previous corresponding period: half-year ended 31 December 2021) To be read in conjunction with the 30 June 2022 Annual Report. In compliance with Listing Rule 4.2A. ABN 90 009 237 889 ASX/Media Release (ASX: IMM) 24 February 2023 Appendix 4D Half-Year Financial |
|
| February 6, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated February 6, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney N |
|
| February 6, 2023 |
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC • 20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination therapy study of efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy • Promising initial efficacy results showing a 72.7% response rate and 90.9% diseas |
|
| January 31, 2023 |
Immutep Quarterly Activities Report & Appendix 4C Q2 FY23 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q2 FY23 • Second US FDA Fast Track designation granted to eftilagimod alpha (efti) supporting planned late-stage development in 1st line non-small cell lung cancer (1L NSCLC) • Compelling Phase II results in 1L NSCLC, including Overall Response Rate (ORR) of 40.4% in all-comer PD-L1 TACTI (Two ACTive Immunotherapies t |
|
| January 31, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated January 30, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney N |
|
| January 4, 2023 |
Exhibit 99.1 ASX/Media Release Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer ? Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha?s potential to address high unmet need for metastatic breast cancer patients ? Patient population expanded to include patients with t |
|
| January 4, 2023 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer SYDNEY, AUSTRALIA – 4 January 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it |
|
| January 4, 2023 |
6-K 1 d422770d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated January 4, 2023 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 Geo |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated December 23, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| December 8, 2022 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by WuXi Biologics SYDNEY, AUSTRALIA – 8 December, 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 i |
|
| December 8, 2022 |
6-K 1 d415743d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated December 8, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 Ge |
|
| December 7, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated December 6, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney N |
|
| December 7, 2022 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease Achievement Allows IND-enabling Studies in 1H’2023 and Subsequent Clinical Testing of IMP761 to Address Root Cause of Autoimmune Diseases SYDNEY, AUSTRALIA – 06 December 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Comp |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 29, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| November 29, 2022 |
Exhibit 99.1 Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer ? New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combinatio |
|
| November 15, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 14, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney |
|
| November 15, 2022 |
Immutep receives Australian R&D Tax Incentive EX-99.1 Exhibit 99.1 ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 14 November 2022 Immutep receives Australian R&D Tax Incentive SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$986,286 (~US$659,303) cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided i |
|
| November 14, 2022 |
Exhibit 99.1 ASX/Media Release Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022 First activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7% response rate and 90.9% disease control rate in 1st line NSCLC patients The triple combination therapy has been well tolerated and appears to be safe SYDNEY, AUSTRALIA ? 11 No |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 11, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| November 14, 2022 |
Global Webcast Presentation (ASX: IMM, NASDAQ: IMMP) Update on new TACTI-002 Phase II and initial INSIGHT-003 Phase 1 data presented at SITC 2022 A Global Leader in LAG-3 Therapeutics in Oncology and Autoimmune Disease Date & Time Thursday, 10 November 2022, at 5 pm U. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 11, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| November 14, 2022 |
Exhibit 99.1 ASX/Media Release Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting Overall response rate (ORR) increases to 40.4%, according to iRECIST, in TACTI-002 all-comer PD-L1 Phase II trial in 1st line non-small cell lung cancer (1L NSCLC) ORR improved across al |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 11, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| November 9, 2022 |
Exhibit 99.1 ASX/Media Release Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination SYDNEY, AUSTRALIA ? 9 November 2022 ? Immutep Limited (ASX: IMM; NASDAQ: IMMP) (?Immutep? or ?the Company?), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased |
|
| November 9, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 09, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney |
|
| November 4, 2022 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference Company to host Webcast on Thursday, 10th November at 5 PM ET to discuss data in Late-Breaking Oral Abstract Pr |
|
| November 4, 2022 |
EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting Oral presentation will detail new clinical data for eftilagimod alpha in combination with pembrolizumab in 1st line NSCLC patients from TACTI-002/KEYNOTE-798 Phase II trial SY |
|
| November 4, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 04, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney |
|
| November 4, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 03, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney |
|
| October 31, 2022 |
Exhibit 12.1 Certification of the Chief Executive Officer and Chief Financial Officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, Marc Voigt, certify that: 1. I have reviewed this annual report on Form 20-F of Immutep Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make |
|
| October 31, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|
| October 31, 2022 |
Exhibit 13.1 Certification of the Chief Executive Officer and Chief Financial Officer as required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. ?1350), Marc Voigt, Chief Executive |
|
| October 31, 2022 |
Description of securities (American Depositary Shares) Exhibit 2.4 DESCRIPTION OF SECURITIES American Depositary Shares The Bank of New York Mellon, as depositary, will register and deliver American Depositary Shares, also referred to as ADSs. Each ADS will represent 10 ordinary shares (or a right to receive 10 ordinary shares) deposited with the principal Melbourne office of HSBC Bank Australia Limited, as custodian for the depositary. Each ADS will |
|
| October 28, 2022 |
EX-99.1 2 d372512dex991.htm EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned SYDNEY, AUSTRALIA – 26 October 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune d |
|
| October 28, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 26, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George Street, Sydney N |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 25, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2 |
|
| October 26, 2022 |
Immutep Quarterly Activities Report & Appendix 4C Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C ? Clinical development strategy for efti to prioritise non-small cell lung cancer (NSCLC), as well as advance head & neck squamous cell cancer (HNSCC) and metastatic breast cancer (MBC) ? Further encouraging interim data in 2nd line NSCLC from TACTI-002 comparing favourably to standard of care chemotherapy-based optio |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 6, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 20 |
|
| October 6, 2022 |
Exhibit 99.1 ASX/Media Release Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting Initial data from INSIGHT-003 trial treating patients with various solid tumours with triple combination therapy of efti, anti-PD-1 therapy, and chemotherapy to be discussed at SITC SYDNEY, AUSTRALIA ? 06 October 2022 ? Immutep Limited (ASX: IMM |
|
| October 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 4, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 20 |
|
| October 5, 2022 |
Exhibit 99.1 ASX/Media Release Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer ? Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancer ? Based on the encouraging Phase II clinical data for PD-L1 all-comers presented at ASCO 2022 ? Marks the |
|
| September 23, 2022 |
Immutep Receives A$2.7 million R&D Tax Incentive from French Government Exhibit 99.1 ASX/Media Release Immutep Receives A$2.7 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA ? 23 September 2022 ? Immutep Limited (ASX: IMM; NASDAQ: IMMP) (?Immutep? or ?the Company?), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a ?1,804,341 (~ A$2,693,046 ) r |
|
| September 23, 2022 |
6-K 1 d406204d6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated September 23, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square |
|
| September 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated September 14, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| September 15, 2022 |
Exhibit 99.1 ASX/Media Release Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha ? Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast cancer (MBC) ? Planning and regulatory interactions on |
|
| September 14, 2022 |
Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board SYDNEY, AUSTRALIA – 13 September 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the appointment of its Chief Scientific Officer and Ch |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated September 13, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| September 7, 2022 |
Exhibit 99.1 ASX/Media Announcement Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma ? Expansion of the efti clinical development pipeline with a new Phase II setting ? Efti Phase II trial awarded ?1.5M (~A$2.2M) in funding as part of the Polish Medical Research Agency program funded by the Polish government ? Collabo |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated September 6, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated August 31, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 20 |
|
| September 1, 2022 |
APPENDIX 4E PRELIMINARY FINAL REPORT Exhibit 99.1 Immutep Limited Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2022 Previous corresponding period: Year ended 30 June 2021 2. Results for announcement to the market FY 2021 FY 2022 Revenue from ordinary activities Up Nil to 170,369 Other income Up 3,968,133 to 6,5 |
|
| August 31, 2022 |
Exhibit 99.1 ASX/Media Release IMMUTEP GRANTED JAPANESE PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA ? 30 August 2022 ? Immutep Limited (ASX: IMM; NASDAQ: IMMP) (?Immutep? or ?the Company?), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announc |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated August 30, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 20 |
|
| August 2, 2022 |
EX-99.1 2 d659801dex991.htm EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X refractory NSCLC • Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC) • Patients in this 2nd line setting had confirmed disease progression on ant |
|
| August 2, 2022 |
6-K 1 d659801d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated August 1, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 Geor |
|
| July 29, 2022 |
Immutep Quarterly Activities Report & Appendix 4C EX-99.1 2 d371370dex991.htm EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C • Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activity • Biomarker and multivariate analysis data from the completed Phase IIb AIPAC trial reported, confirming |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated July 28, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2000 |
|
| July 7, 2022 |
ASX/Media Release IMMUTEP GRANTED JAPANESE PATENT FOR IMP761, A FIRST-IN-CLASS IMMUNOSUPPRESSIVE ANTIBODY TARGETING LAG-3 SYDNEY, AUSTRALIA ? 6 July 2022 ? Immutep Limited (ASX: IMM; NASDAQ: IMMP) (?Immutep? or ?the Company?), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 7074341) entitled ?Anti-LAG-3 Antibodies? by the Japanese Patent Office. |
|
| July 7, 2022 |
6-K 1 d328207d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated July 6, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George |
|
| June 28, 2022 |
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer Exhibit 99.1 ASX/Media Release Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer SYDNEY, AUSTRALIA ? 27 June 2022 ? Immutep Limited (ASX: IMM; NASDAQ: IMMP) (?Immutep? or ?the Company?), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new data from second line non-small cell lung cancer pa |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated June 27, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2000 |
|
| June 7, 2022 |
Exhibit 99.1 ASX/Media Release Immutep reports positive Overall Response Rate in its Phase II clinical trial in 1st line NSCLC for PD-L1 all-comers ? TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducted in collaboration with MSD (N=114) ? Combination of efti plus pembrolizumab shows favourable anti-t |
|
| June 7, 2022 |
6-K 1 d318994d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated June 6, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated May 27, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2000, |
|
| May 31, 2022 |
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022 Exhibit 99.1 ASX/Media Release Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022 ? Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1st line non-small cell lung cancer (NSCLC) patients from TACTI-002 with data cut off January 2022 ? Improved Overall Response Rate (ORR) of 37.3% (intent to treat, 28/75 patients) as assessed by l |
|
| May 18, 2022 |
6-K 1 d348482d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated May 18, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 George |
|
| May 18, 2022 |
Immutep Appoints Leading Oncologists to its Clinical Advisory Board Exhibit 99.1 ASX/Media Release Immutep Appoints Leading Oncologists to its Clinical Advisory Board SYDNEY, AUSTRALIA ? 18 May 2022 ? Immutep Limited (ASX: IMM; NASDAQ: IMMP) (?Immutep? or ?the Company?), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced today the appointment of four new members to the Company?s Clinical Ad |
|
| May 5, 2022 |
Immutep presents new and significant data from the AIPAC study Exhibit 99.1 ASX/Media Release Immutep presents new and significant data from the AIPAC study ? Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) demonstrated in the efti group, but not in the placebo group ? The increase in pharmacodynamic markers is significantly linked |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated May 4, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 2000, |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated April 29, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 200 |
|
| May 2, 2022 |
Immutep Quarterly Activities Report & Appendix 4C Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C ? New interim TACTI-002 data from 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients shows encouraging early overall survival rate of 73.7% at the six-month landmark ? Constructive feedback from the US FDA regarding the clinical development program for efti in metastatic breast cancer (MBC) ? New inter |
|
| April 28, 2022 |
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting Exhibit 99.1 ASX/Media Release Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting SYDNEY, AUSTRALIA ? 28 April 2022 ? Immutep Limited (ASX: IMM; NASDAQ: IMMP) (?Immutep? or ?the Company?), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new interim data from first line non-small |
|
| April 28, 2022 |
6-K 1 d354646d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated April 28, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 Geor |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated March 30, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 200 |
|
| March 31, 2022 |
Exhibit 99.1 ASX/Media Release Immutep?s efti in combination with MSD?s pembrolizumab shows encouraging antitumor activity in difficult to treat 2nd line metastatic lung cancer patients ? All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior PD-1 or PD-L1 therapy (PD-X refractory) ? Encouraging interim Disea |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated March 24, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 200 |
|
| March 25, 2022 |
Immutep announces publication of TACTI-002 abstract at ESMO’s European Lung Cancer Congress 2022 Exhibit 99.1 ASX/Media Release Immutep announces publication of TACTI-002 abstract at ESMO?s European Lung Cancer Congress 2022 ? New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in 2nd line, confirmed PD-1/PD-L1 refractory, non-small cell lung cancer (NSCLC) patients ? Combination continues to be safe and well tolerated, and shows encouraging signs of |
|
| March 21, 2022 |
IMMUTEP ANNOUNCES SECOND JAPANESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 Exhibit 99.1 ASX/Media Release IMMUTEP ANNOUNCES SECOND JAPANESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 SYDNEY, AUSTRALIA ? 18 March 2022 ? Immutep Limited (ASX: IMM; NASDAQ: IMMP) (?Immutep? or ?the Company?), is pleased to announce the grant of patent no. 7030750 entitled ?Antibody molecules to LAG-3 and uses thereof? by the Japanese Patent Office. This new Japanese patent was filed a |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated March 18, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW 200 |
|
| March 10, 2022 |
6-K 1 d328122d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated March 10, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 Geor |
|
| March 10, 2022 |
Exhibit 99.1 ASX/Media Release IMMUTEP RECEIVES CONSTRUCTIVE FEEDBACK FROM US FDA ON ITS CLINICAL DEVELOPMENT PROGRAM FOR EFTI IN METASTATIC BREAST CANCER SYDNEY, AUSTRALIA ? 10 March 2022 ? Immutep Limited (ASX: IMM; NASDAQ: IMMP) (?Immutep? or ?the Company?), is pleased to announce it has received constructive feedback from the US Food and Drug Administration (FDA) regarding its clinical develop |
|
| February 24, 2022 |
Exhibit 99.1 IMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2021 (previous corresponding period: half-year ended 31 December 2020) To be read in conjunction with the 30 June 2021 Annual Report. In compliance with Listing Rule 4.2A. ABN 90 009 237 889 ASX/Media Release (ASX: IMM) 23 February 2022 Appendix 4D Half-Year Financial Report R |
|
| February 24, 2022 |
6-K 1 d279363d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated February 23, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Level 33, Australia Square 264 G |
|
| February 24, 2022 |
Exhibit 99.1 ASX/Media Release IMMUTEP GRANTED AUSTRALIAN PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA ? 11 February 2022 ? Immutep Limited (ASX: IMM; NASDAQ: IMMP) (?Immutep? or ?the Company?), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to ann |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated February 24, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 33, Australia Square 264 George Street, Sydney NSW |
|
| January 25, 2022 |
Immutep Quarterly Activities Report & Appendix 4C EX-99.1 2 d642142dex991.htm EX-99.1 Exhibit 99.1 ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C • Final Overall Survival data from AIPAC Phase IIb trial reported at the SITC 2021 conference, supporting Immutep’s planned Phase III clinical development of efti in combination with paclitaxel in metastatic breast cancer • Encouraging antitumor activity also reported from TACTI-002 |
|
| January 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated January 25, 2022 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 12, 95 Pitt Street Sydney, 2000 New South Wales, Aus |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated December 16, 2021 Commission File Number 001-35428 IMMUTEP LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) Level 12, 95 Pitt Street Sydney, 2000 New South Wales, Au |
